Integrated Investment Consultants LLC Sells 1,391 Shares of Amgen Inc. $AMGN

Integrated Investment Consultants LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 40.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,051 shares of the medical research company’s stock after selling 1,391 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Amgen were worth $579,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC boosted its stake in Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after acquiring an additional 3,619 shares during the last quarter. Davis Capital Management bought a new stake in shares of Amgen during the 3rd quarter valued at $1,841,000. D.A. Davidson & CO. lifted its stake in shares of Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after purchasing an additional 6,222 shares during the period. Global Wealth Management Investment Advisory Inc. lifted its stake in shares of Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after purchasing an additional 4,699 shares during the period. Finally, Jones Financial Companies Lllp boosted its position in shares of Amgen by 18.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after purchasing an additional 6,115 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of Amgen stock opened at $361.13 on Wednesday. The stock’s fifty day simple moving average is $359.26 and its 200 day simple moving average is $326.77. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company has a market capitalization of $194.67 billion, a PE ratio of 25.38, a PEG ratio of 3.63 and a beta of 0.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the firm earned $5.31 earnings per share. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen’s payout ratio is currently 70.84%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported stronger-than-expected results and raised FY guidance, supporting fundamentals and cash flow — a key reason some investors remain constructive. MarketBeat Earnings & Guidance
• Positive Sentiment: Analysts lifted Amgen’s fair-value estimate on growing confidence in execution and the MariTide obesity program, which boosts upside expectations if clinical/exclusivity risks are managed. Yahoo: Narrative Shifting
• Positive Sentiment: Large investor interest: Ken Fisher’s firm increased its Amgen stake, a vote of confidence from a prominent institutional investor. Yahoo: Ken Fisher Doubles Position
• Neutral Sentiment: Amgen is being watched by retail and professional traders (trending coverage), which can amplify moves but doesn’t by itself change fundamentals. Zacks: Trending Stock
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent/zeroed out and is not signaling a clear squeeze or covering dynamic at this time.
• Neutral Sentiment: Amgen’s shares were reported to outperform many peers on a relative-basis despite the intraday decline, indicating sector/stock-specific flows rather than a company-specific collapse. MarketWatch: Outperforms Peers
• Negative Sentiment: Amgen (with peers) is reportedly joining a drug-discount initiative (TrumpRx), which could pressure pricing and margins for certain products if discounts are material. Benzinga: TrumpRx Participation
• Negative Sentiment: Analyst upgrades and MariTide optimism are tempered by exclusivity and long-term earnings debate — unresolved regulatory/IP questions could cap upside until clearer trial and exclusivity outcomes arrive. Yahoo: Exclusivity Concerns

Analyst Ratings Changes

AMGN has been the subject of a number of analyst reports. The Goldman Sachs Group lifted their price objective on Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. HSBC restated a “buy” rating and set a $425.00 target price on shares of Amgen in a research report on Wednesday, December 10th. Guggenheim upped their price target on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Finally, Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $354.00.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.